Liontrust Investment Partners LLP lowered its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 18.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 98,662 shares of the medical equipment provider’s stock after selling 21,858 shares during the period. Liontrust Investment Partners LLP’s holdings in Boston Scientific were worth $6,191,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of BSX. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the fourth quarter worth $26,000. Bangor Savings Bank grew its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the first quarter valued at $28,000. Institutional investors own 89.07% of the company’s stock.
Boston Scientific Stock Performance
Boston Scientific stock opened at $45.92 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $68.25 billion, a PE ratio of 18.59, a P/E/G ratio of 0.89 and a beta of 0.58. The firm has a fifty day simple moving average of $46.35 and a two-hundred day simple moving average of $62.37. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.
Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.
Insider Activity at Boston Scientific
In related news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 9,800 shares of company stock worth $554,012 in the last ninety days. 0.34% of the stock is owned by company insiders.
Key Stories Impacting Boston Scientific
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported revenue of $5.442 billion, up 7.5% year over year, and adjusted earnings of $0.86 per share versus the $0.83 consensus estimate. Cardiovascular sales increased 8.3%, while international growth was particularly strong in APAC and LACA. Boston Scientific announces results for second quarter 2026
- Positive Sentiment: Cost savings and product development may support longer-term growth. Boston Scientific is pursuing a multiyear restructuring program targeting approximately $500 million in annual savings, received FDA clearance for its TruSelect 2.6 Microcatheter and invested $1.5 billion in MiRus, including an option to acquire its TAVR business. The company also completed a $2 billion accelerated share repurchase.
- Positive Sentiment: Analysts remain broadly bullish despite lower targets. TD Cowen, Truist and BTIG retained “buy” ratings, while UBS reaffirmed its “buy” rating. However, their price targets were reduced to reflect more cautious near-term assumptions. What Are Wall Street Analysts’ Target Price for Boston Scientific Stock?
- Neutral Sentiment: Boston Scientific is acquiring Penumbra. Penumbra reported second-quarter revenue of $390.0 million, up 14.9%, with gross margin improving to 67.9%. The company will not provide full-year guidance or hold a conference call because of the pending acquisition by Boston Scientific. The deal could expand BSX’s thrombectomy and embolization portfolio, but integration and transaction costs remain factors for investors. Penumbra, Inc. Reports Second Quarter 2026 Financial Results
- Negative Sentiment: Lower guidance overshadowed the quarterly beat. Boston Scientific now expects full-year adjusted EPS of $3.28–$3.32, below the prior $3.34–$3.41 range and analyst expectations of roughly $3.36. Third-quarter EPS and revenue guidance also fell short of consensus.
- Negative Sentiment: WATCHMAN and electrophysiology headwinds are weighing on expectations. Softer WATCHMAN demand, competition and slower EP growth prompted management to temper its outlook. The company also faces a product recall and expects restructuring costs of approximately $700 million to $800 million through 2029. Boston Scientific trims annual profit forecast on softer Watchman device demand
Wall Street Analysts Forecast Growth
BSX has been the topic of a number of research reports. TD Cowen lowered their price target on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday. Mizuho cut their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Royal Bank Of Canada reduced their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research report on Wednesday. Finally, Oppenheimer dropped their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.
Read Our Latest Stock Analysis on Boston Scientific
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
- Five stocks we like better than Boston Scientific
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
